Company record · updated August 5, 2026
Kailera Therapeutics, Inc.: 4 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs March 27, 2026 to March 27, 2026.
4observations
1source filings
4verified rows
2026-03-27most recent as-of date
Source rails for this company: S-1 charter round (4).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-03-27 | Series B price per share | 14 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312526128952 |
| 2026-03-27 | Series A-2 price per share | 10 USD | — | VERIFIED | "Original Issue Price" defined for Series A-2 | 000119312526128952 |
| 2026-03-27 | Series A-1 price per share | 10 USD | — | VERIFIED | "Original Issue Price" defined for Series A-1 | 000119312526128952 |
| 2026-03-27 | Series A price per share | 10 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312526128952 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.